OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
BCDA$1.0958

BioCardia Inc

Biotechnology & Medical ResearchVerified

Capital Structure and Liquidity BioCardia has a negative net equity position of $1.96 million, indicating a significant deficit in its capital structure. The company's cash and equivalents amount to $1.42 million, which is insufficient to cover its total liabilities of $4.85 million, resulting in a current ratio of 0.39. This low liquidity position suggests the company may face challenges in meeting its short-term obligations without external financing. ### Profitability and Returns The company reported a net loss of $1.65 million and an operating loss of $1.65 million, reflecting poor profitability. The return on equity (ROE) is 0.8394, which is exceptionally low, and the return on assets (ROA) is -0.5696, indicating that the company is not generating returns from its asset base. These metrics are well below industry norms for biotechnology firms, which typically require significant R&D investment before achieving profitability. ### Segments and Geographic Exposure BioCardia's financial data does not provide detailed segment or geographic revenue breakdowns. However, the company's primary operations are likely concentrated in the United States, given its listing on the NASDAQ and the absence of international revenue disclosures. This lack of diversification increases its exposure to domestic market risks. ### Growth Trajectory The company's revenue for the latest period is $3.00 million, but it is operating at a significant loss. Analysts have provided a mean price target of $15.50, which is substantially higher than the current market price of $1.09. This suggests that analysts expect a significant turnaround in the company's performance, although the current financials do not support such optimism. ### Risk Factors The risk assessment indicates low liquidity and dilution risks, but the company's negative net equity and high operating losses pose significant financial risks. The absence of long-term debt is a positive factor, but the company's reliance on cash reserves to fund operations is a concern. There are no immediate filing-based liquidity or dilution flags, but the company's financial position remains precarious. ### Recent Events Recent filings and transcripts do not indicate any major events that would significantly impact the company's financial position. However, the company's ongoing losses and limited cash reserves suggest that it may need to secure additional financing in the near future to continue operations.

30-day price · BCDA(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyBioCardia Inc
TickerBCDA.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. BioCardia Inc is a biotechnology company focused on developing and commercializing cell therapy and regenerative medicine technologies for the treatment of cardiovascular diseases.

Classification. BioCardia is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a confidence level of 0.92.

### Capital Structure and Liquidity BioCardia has a negative net equity position of $1.96 million, indicating a significant deficit in its capital structure. The company's cash and equivalents amount to $1.42 million, which is insufficient to cover its total liabilities of $4.85 million, resulting in a current ratio of 0.39. This low liquidity position suggests the company may face challenges in meeting its short-term obligations without external financing. ### Profitability and Returns The company reported a net loss of $1.65 million and an operating loss of $1.65 million, reflecting poor profitability. The return on equity (ROE) is 0.8394, which is exceptionally low, and the return on assets (ROA) is -0.5696, indicating that the company is not generating returns from its asset base. These metrics are well below industry norms for biotechnology firms, which typically require significant R&D investment before achieving profitability. ### Segments and Geographic Exposure BioCardia's financial data does not provide detailed segment or geographic revenue breakdowns. However, the company's primary operations are likely concentrated in the United States, given its listing on the NASDAQ and the absence of international revenue disclosures. This lack of diversification increases its exposure to domestic market risks. ### Growth Trajectory The company's revenue for the latest period is $3.00 million, but it is operating at a significant loss. Analysts have provided a mean price target of $15.50, which is substantially higher than the current market price of $1.09. This suggests that analysts expect a significant turnaround in the company's performance, although the current financials do not support such optimism. ### Risk Factors The risk assessment indicates low liquidity and dilution risks, but the company's negative net equity and high operating losses pose significant financial risks. The absence of long-term debt is a positive factor, but the company's reliance on cash reserves to fund operations is a concern. There are no immediate filing-based liquidity or dilution flags, but the company's financial position remains precarious. ### Recent Events Recent filings and transcripts do not indicate any major events that would significantly impact the company's financial position. However, the company's ongoing losses and limited cash reserves suggest that it may need to secure additional financing in the near future to continue operations.
Key takeaways
  • BioCardia is operating at a significant loss with a negative net equity position.
  • The company's liquidity position is weak, with a current ratio of 0.39.
  • Analysts have set a high mean price target of $15.50, indicating expectations for a significant turnaround.
  • The company lacks detailed segment and geographic revenue disclosures, increasing its exposure to domestic market risks.
  • The absence of long-term debt is a positive factor, but the company's reliance on cash reserves is a concern.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$3.0k
Gross profit
Operating income-$1.6M
Net income-$1.6M
R&D
SG&A
D&A
SBC
Operating cash flow-$2.8M
CapEx-$3.0k
Free cash flow-$1.6M
Total assets$2.9M
Total liabilities$4.9M
Total equity-$2.0M
Cash & equivalents$1.4M
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$1.0M-$12.6M-$12.6M-$12.7M
FY-3$1.4M-$11.9M-$11.9M-$11.9M
FY-2$477.0k-$11.6M-$11.6M-$11.5M
FY-1$58.0k-$8.0M-$7.9M-$7.9M
FY0$0.00-$8.3M-$8.2M-$8.2M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$15.7M$10.4M$12.9M
FY-3$9.8M$4.9M$7.4M
FY-2$3.0M-$1.6M$1.1M
FY-1$3.7M$837.0k$2.4M
FY0$3.4M$895.0k$2.5M
PeriodOCFCapExFCFSBC
FY-4-$10.4M-$116.0k-$12.7M
FY-3-$10.6M-$70.0k-$11.9M
FY-2-$10.0M-$12.0k-$11.5M
FY-1-$8.0M-$6.0k-$7.9M
FY0-$7.4M-$7.0k-$8.2M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$3.0k-$1.6M-$1.6M-$1.6M
FQ-6$0.00-$1.8M-$1.7M-$1.7M
FQ-5$0.00-$2.3M-$2.3M-$2.3M
FQ-4$0.00-$2.7M-$2.7M-$2.7M
FQ-3$0.00-$2.1M-$2.0M-$2.0M
FQ-2-$1.5M-$1.5M-$1.5M
FQ-1$0.00-$2.0M-$2.0M-$2.0M
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$2.9M-$2.0M$1.4M
FQ-6$6.3M$2.8M$4.9M
FQ-5$3.7M$837.0k$2.4M
FQ-4$2.2M-$1.5M$949.0k
FQ-3$2.1M-$1.9M$980.0k
FQ-2$6.1M$2.6M$5.3M
FQ-1$3.4M$895.0k$2.5M
FQ0
PeriodOCFCapExFCFSBC
FQ-7-$2.8M-$3.0k-$1.6M
FQ-6-$5.5M-$5.0k-$1.7M
FQ-5-$8.0M-$6.0k-$2.3M
FQ-4-$1.6M-$2.7M
FQ-3-$3.3M-$1.0k-$2.0M
FQ-2-$4.9M-$1.0k-$1.5M
FQ-1-$7.4M-$7.0k-$2.0M
FQ0
Valuation
Market price$1.09
Market cap$11.9M
Enterprise value$10.5M
P/E
Reported non-GAAP P/E
EV/Revenue3501.3
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$2.0M
Net cash$1.4M
Current ratio0.4
Debt/Equity-0.0
ROA-57.0%
ROE83.9%
Cash conversion1.7%
CapEx/Revenue-1.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricBCDAActivity
Op margin-54966.7%2.4% medp25 -91.8% · p75 12.5%bottom quartile
Net margin-54866.7%1.2% medp25 -98.4% · p75 10.4%bottom quartile
Gross margin45.6% medp25 29.8% · p75 66.7%
CapEx / revenue-100.0%-5.2% medp25 -15.8% · p75 -1.7%bottom quartile
Debt / equity-0.0%9.3% medp25 0.1% · p75 43.8%bottom quartile
Observations
IR observations
Mean price target15.50 USD
Median price target15.50 USD
High price target25.00 USD
Low price target6.00 USD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count2.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.63 USD
Last actual EPS-1.23 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-17 00:17 UTC#399aa67f
Market quoteclose USD 1.11 · shares 0.01B diluted
no public URL
2026-05-17 00:18 UTC#d9b6ffaa
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 11:23 UTCJob: 770955f4